Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1Phase 3 1

Status

Terminated 3Completed 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Neoplasms 5Melanoma 4Carcinoma, Renal Cell 4Lymphoma, Follicular 3Lymphoma 3Sarcoma 2Lymphoma, Non-Hodgkin 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Carcinoma, Hepatocellular 2Zollinger-Ellison Syndrome 1Virus Diseases 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Philadelphia Chromosome 1Multiple Myeloma 1Meningeal Carcinomatosis 1Lymphoproliferative Disorders 1Lymphomatoid Granulomatosis 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Kidney Neoplasms 1Influenza, Human 1Hepatitis B, Chronic 1Hepatitis B 1Heartburn 1Gastrointestinal Cancer Metastatic 1Epstein-Barr Virus Infections 1

Interventions

Sunitinib 145Nivolumab 144pembrolizumab 132Sorafenib 84Bevacizumab 77Everolimus 74cabozantinib 71pazopanib 65Axitinib 65Ipilimumab 62aldesleukin 52Magnetic Resonance Spectroscopy 45Cyclophosphamide 40Interleukin-2 38lenvatinib 37Specimen Handling 36Radiosurgery 36Interferon-alpha 32atezolizumab 30temsirolimus 27belzutifan 24Gemcitabine 23fludarabine phosphate 22avelumab 22Radiotherapy 19Interferon alpha-2 19Biopsy 18fludarabine 17durvalumab 17Nephrectomy 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Carcinoma, Renal Cell × Interferons × Clear all
NCT00352859 2014-12-30

Phase IV Randomization to On-Going Treatment to Evaluate Sustained Sorafenib

Bayer

Phase 4 Terminated
2 enrolled
Genitourinary

Carcinoma, Renal Cell, Neoplasms

NCT00678288 2014-12-11

A Study to Assess Sorafenib Alone and in Combination With Low-Dose Interferon Following Unsuccessful Treatment With Sunitinib in Patients With Advanced Renal Cell Cancer.

Bayer

Phase 2 Terminated
16 enrolled 6 charts
Genitourinary

Carcinoma, Renal Cell

NCT00117637 2014-10-31

BAY43-9006 (Sorafenib) Versus Interferon Alpha-2a in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma

Bayer

Phase 2 Completed
189 enrolled 44 charts
Genitourinary

Carcinoma, Renal Cell, Neoplasms

NCT00311467 2012-05-16

Combined Treatment With Capecitabine and Immunotherapy Versus Immunotherapy Alone in Advanced Renal Cell Carcinoma

Central European Cooperative Oncology Group

Phase 3 Terminated
172 enrolled
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡